首页 News 正文

On March 15th, Pfizer announced that its innovative tumor immunotherapy drug, Serenigme (Shuglizumab Injection), has been approved by the National Medical Products Administration for first-line treatment of locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma (G/GEJ) expressing PD-L1, in combination with fluorouracil and platinum containing drugs, Becoming the world's first PD-L1 monoclonal antibody approved for indication in gastric/gastroesophageal junction adenocarcinoma.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

123458015 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    3